What is Otonomy?
Otonomy is dedicated to developing innovative therapeutics for neurotology, a field addressing conditions of the ear, nose, and throat. The company's core innovation lies in its proprietary drug delivery technology, designed to achieve sustained drug exposure from a single local administration. This approach, protected by a robust patent estate, aims to address critical unmet medical needs, particularly in the areas of hearing loss and tinnitus. The company's pipeline is built upon this foundational technology, positioning it as a key player in the specialized biopharmaceutical market.
How much funding has Otonomy raised?
Otonomy has raised a total of $448.4M across 7 funding rounds:
Series A
$10M
Series B
$38.5M
Series C
$45.9M
Series D
$49M
Stock Offering
$104M
Stock Offering
$86M
Stock Offering
$115M
Series A (2010): $10M with participation from Avalon Ventures
Series B (2010): $38.5M led by Domain Associates, TPG Biotech, RiverVest Venture Partners, Avalon Ventures, and Novo Ventures
Series C (2013): $45.9M supported by APERTURE Venture Partners, Osage University Partners, RiverVest Venture Partners, Domain Associates, OrbiMed, TPG Biotech, Avalon Ventures, and Novo Ventures
Series D (2014): $49M featuring APERTURE Venture Partners, Jennison Associates, Domain Associates, OrbiMed, TPG Biotech, Clough Capital Partners, Avalon Ventures, RiverVest Venture Partners, Federated Kaufmann Funds, Perceptive Advisors, Ally Bridge Group, Osage University Partners, and Novo Ventures
Stock Issuance/Offering (2014): $104M backed by Undisclosed
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Stock Issuance/Offering (2016): $115M led by Undisclosed
Key Investors in Otonomy
APERTURE Venture Partners
APERTURE Venture Partners is a healthcare-focused investment firm dedicated to collaborating with exceptional entrepreneurs to develop innovative companies in the medical device, pharmaceutical, healthcare IT/services, and diagnostic sectors. The firm boasts partners with extensive industry knowledge and a proven track record of success in helping companies reach their potential.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies.
TPG Biotech
TPG is widely regarded as a global investment firm that focuses on managing alternative assets and supporting business growth across diverse industries. From a third-party perspective, it is seen as a firm that provides investment management, advisory, and capital solutions to institutions and companies worldwide. It operates across areas such as private equity, credit, real estate, and impact investing, helping organizations expand and improve performance.
What's next for Otonomy?
The recent major strategic investment signals a pivotal phase for Otonomy, likely enabling the company to advance its pipeline candidates through critical clinical trials and toward potential commercialization. This infusion of capital will be instrumental in scaling operations, expanding research and development efforts, and potentially forging strategic partnerships. As Otonomy continues to navigate the complex biopharmaceutical landscape, its focus on innovative drug delivery for otological conditions positions it for continued growth and impact in addressing significant patient needs.
See full Otonomy company page
